The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.

Boccia, Ralph

The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. [electronic resource] - The oncologist May 2007 - 584-93 p. digital

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1083-7159

10.1634/theoncologist.12-5-584 doi


Activities of Daily Living
Adult
Age Factors
Aged
Aged, 80 and over
Anemia--blood
Antineoplastic Agents--adverse effects
Biomarkers--blood
Darbepoetin alfa
Drug Administration Schedule
Erythrocyte Transfusion
Erythropoietin--administration & dosage
Fatigue--chemically induced
Female
Follow-Up Studies
Hematinics--administration & dosage
Hemoglobins--drug effects
Humans
Karnofsky Performance Status
Male
Middle Aged
Neoplasms--drug therapy
Quality of Life
Research Design
Surveys and Questionnaires
Treatment Outcome